Search

Angiogenesis inhibition is a key step towards the designing of new chemotherapeutic agents. In a view to preparing new molecular entities for cancer treatment, eighteen 1,2,3-triazole-uracil ensembles 5a–r were designed and synthesized via the click reaction. The ligands were well characterized using 1H-, 13C-NMR, elemental analysis and ESI-mass spectrometry. The in silico binding propinquities of the ligands were studied sequentially in the active region of VEGFR-2 using the Molegro virtual docker. All the compounds produced remarkable interactions and potentially inhibitory ligands against VEGFR-2 were obtained with high negative binding energies. Drug-likeness was assessed from the ADME properties. Cytotoxicity of the test compounds was measured against HeLa and HUH-7 tumor cells and NIH/3T3 normal cells by MTT assay. Compound 5h showed higher growth inhibition activity than the positive control, 5-fluorouracil (5-FU), against both HeLa and HUH-7 cells with IC50 values of 4.5 and 7.7 μM respectively. Interestingly, the compounds 5a–r did not show any cytotoxicity towards the normal cell lines. The results advance the position of substituted triazoles in the area of drug design with no ambiguity.

Ten mononuclear Rhodium (I) complexes were synthesized by macrocyclic ligands having N4 and N2O2 donor sites. Square planar geometry is assigned based on the analytical and spectral properties for all complexes. Rh(I) complexes were investigated as catalysts in hydrolysis of Nitrile group containing pharmaceutical drug Letrozole. A comparative study showed that all the complexes are efficient in the catalysis. The percent yields of all the catalytic reaction products viz. drug impurities were determined by spectrophotometric procedures and characterized by spectral studies.

The synthesis and characterization for a series of symmetrical 1,3-dialkylimidazolium salts with different chain lengths and counter anions together with their 1-alkylimidazole precursors are described. Liquid crystal (LC) properties of these salts are studied. Images under polarizing optical microscopy show focal conic texture together with homeotropic domains. A smectic A mesophase, typical for rod-like imidazolium salts, is assigned. Studies from powder X-ray diffraction suggest a lamellar structure with noninterdigitated monolayer arrangement for the LC salts in the mesophase. In addition, a short note on the structure and property relationship for rod-like, disc- or fan-like, and dendritic shaped imidazolium ionic liquid crystals (ImILCs) forming smectic, columnar, and cubic phase is briefly summarized. A comparison of minimum alkyl chain length needed for 1-alkyl-3-methyl and symmetrical 1,3-dialkyl ImILCs to exhibit LC behavior is addressed.

A series of 6-arylbenzimidazo[1,2-c]quinazoline compounds (11-20) were synthesised by the condensation of 2-(o-aminophenyl)benzimidazole with different arylaldehydes, followed by oxidative cyclisation of the resulting 2-o-arylideneaminophenylbenzimidazoles (1-10). All the products were characterized via IR, ¹H NMR, 13C NMR, MS and elemental analysis. The antimicrobial activities of all 6-arylbenzimidazo [1,2-c]quinazolines against three Gram-positive (S. aureus, B. subtilis, S. pyogenes), three Gram-negative (S. typhimurium, E. coli, K. pneumonia) bacteria and three fungal strains (A. niger, C. albicans, T. viridae) were evaluated. Among the compounds tested 13, 19 and 20 showed most potent inhibitory action against test organisms. Uma série de compostos 6-arilbenzimidazo[1,2-c]quinazolina (11-20) foram sintetizados pela condensação do 2-(o-aminofenil)benzimidazol com diferentes arilaldeídos seguida pela ciclização oxidativa dos 2-o-arilidenoaminofenilbenzimidazol (1-10). Todos os produtos foram caracterizados por espectroscopia no infravermelho (IR), ressonância magnética nuclear de prótons e de carbono, (RMN ¹H e RNN 13C), de massas (MS) e análise elementar. A atividade antimicrobial de todos os 6-arilbenzimidazo[1,2-c]quinazolina foi testada com três linhagens de bactérias Gram-positivas (S. aureus, B. subtilis e S. pyogenes), três Gram-negativas (S. typhimurium, E. coli e K. pneumonia) e de três linhagens de fungos (A. niger, C. albicans e T. viridae). Dos compostos testados, o 13, o 19 e o 20 mostraram-se ser os mais potentes inibidores contra os organismos testados.

A convenient three-step strategy is proposed for the synthesis of mono and bis-indolo[1,2-c] quinazolines from 2-(2-aminophenyl)indole and various aryl aldehydes. The newly synthesized compounds were characterized by elemental analysis, IR, 1H NMR, 13C NMR, and mass spectroscopic investigation. All the derivatives were screened for antibacterial (S. aureus, B. subtilis, S. pyogenes, S. typhimurium, E. coli, K. pneumonia) and antifungal (A. niger, C. albicans, T. viridae) activities by cup plate method. Among the compounds tested, mono- indolo[1,2-c] quinazolines (15-18) exhibited good antibacterial activities while 15 and 18 also showed notable antifungal activity. Especially, 19 and 20 exhibited stronger antibacterial as well as antifungal activity against all tested strains.

A macrocyclic Schiff base nickel(ii) complex was synthesised via template synthesis by treating acetylacetone with 1,8-diaminonaphthalene in the presence of nickel chloride in a 2:2:1 ratio in an aqueous methanol solution at 75 °C for 30 min. It was characterised by elemental, infrared, proton and carbon nuclear magnetic resonance and mass spectral analysis and used as a catalyst for the reduction of tinidazole. The reduced tinidazole was treated with nitrous acid and 2-naphthol and the resulting azo dye was used for the spectrophotometric determination of the reduction product of tinidazole.

New macrocyclic Schiff base Pd(II) compounds were synthesized by treating N4 and N2O2 macrocycles with palladium chloride in a 1 : 1 ratio. The resulting macrocyclic compounds were characterized by elemental, IR, 1H-NMR, 13C-NMR, mass, molar conductance, magnetic susceptibility, electronic spectra, and thermal analysis. These compounds were used as catalysts in the development of an efficient catalytic method for reduction of organic substrates having nitro, olefinic, acetylenic, and aldehyde groups under mild reaction conditions. The biological activities of all the macrocycles and macrocyclic Pd(II) compounds have been tested against gram positive (Bacillus subtilis and Staphylococcus aureus) and gram negative (Escherichia coli and Klebsiella pneumonia) bacteria and found to be more active than commercially available antibacterial drugs like Streptomycin and Ampicillin.

With the aim of obtaining novel biologically active compounds, we have synthesized a series of mono, bis-2-o-arylideneaminophenylbenzimidazoles and a second series of corresponding mono, bis-6-arylbenzimidazo[1,2-c]quinazolines respectively. The target benzimidazo[1,2-c]quinazoline compounds were obtained by the condensation of 2-(o-aminophenyl)benzimidazole with mono and di carbonyl compounds, followed by oxidative cyclisation of the resulting mono and bis-2-o-arylideneaminophenylbenzimidazoles.All the products were characterized via IR, (1)H NMR, (13)C NMR, MS and elemental analysis. The antimicrobial activities of all quinazolines against various bacteria and fungi were evaluated. Among the compounds tested IVd, IVe exhibited good antibacterial and antifungal activities while IIIb, IIIc also showed notable antimicrobial activity with reference to standard drugs Ampicillin and Ketoconazole respectively.

Reactions of [RuCl2(DMSO)4] with some of the biologically active macrocyclic Schiff base ligands containing N4 and N2O2 donor group yielded a number of stable complexes, effecting complete displacement of DMSO groups from the complex. The interaction of tetradentate ligand with [RuCl2(DMSO)4] gave neutral complexes of the type [RuCl2(L)] [where L=tetradentate macrocyclic ligand]. These complexes were characterized by elemental, IR, 1H, 13C NMR, mass, electronic, thermal, molar conductance and magnetic susceptibility measurements. An octahedral geometry has been proposed for all complexes. All the macrocycles and macrocyclic Ru(II) complexes along with existing antibacterial drugs were screened for antibacterial activity against Gram +ve (Bacillus subtilis, Staphylococcus aureus) and Gram -ve (Escherichia coli, Klebsiella pneumonia) bacteria. All these compounds were found to be more active when compared to streptomycin and ampicillin. The representative macrocyclic Schiff bases and their complexes were also tested in vitro to evaluate their activity against fungi, namely, Aspergillus flavus and Fusarium species.

A series of novel macrocyclic compounds were synthesized by the condensation of o-phthalaldehyde with aromatic amino alcohols followed by treatment with 1,2-dibromoethane or 1,3-dibromopropane in non-template method. The structural features of the isolated macrocycles have been determined from the microanalytical, IR, (1)H, (13)C NMR and mass spectral studies. Antimicrobial activities of these macrocyclic compounds were tested against the gram-positive (Bacillus subtilis, Staphylococcus aureus) and gram-negative (Escherichia coli, Klebsiella pneumoniae) bacteria and found to exhibit potential antibacterial activity. The macrocycles were also tested in vitro to evaluate their activity against fungi, namely, Aspergillus flavus (A. flavus) and Fusarium species.

Some new organometallics of ruthenium(II) of the type [RuCl 2 (COD)(CO)L] ( 1a–f ) and [RuCl 2 (COD)L 2 ] ( 2a–f ) (where L is substituted tertiary phosphines), have been synthesized by using precursors [RuCl 2 (COD)(CO)(CH 3 CN)] ( 1 ) and [RuCl 2 (COD)(CH 3 CN) 2 ] ( 2 ) with the substituted tertiary phosphine ligands in 1:1 and 1:2 molar ratio. The organometallics ( 2a–f ) have been further reacted with carbonmonoxide to produce compounds of the type [RuCl 2 (CO)L 2 ] ( 3a–f ). These compounds were characterized by elemental analysis, IR, NMR ( 1 H, 13 C and 31 P), mass and electronic spectral data. The catalytic activity of all these organometallics were studied and found that they are efficient catalysts for hydrolysis of etofibrate. The hydrolyzed product was separated by column chromatography and the percent yields are found in the range of 98.6–99.1%.

Efficient catalytic method for the reduction of pralidoxime to its amine derivative by macrocyclic Ni(II) compounds has been developed. Ten macrocyclic Schiff base Ni(II) compounds were synthesized via non-template synthesis by treating the corresponding macrocycles with nickel chloride in 1:1 ratio. The resulting compounds were characterized by elemental, IR, 1H NMR, 13C NMR, mass, electronic spectra, conductance, magnetic, thermal studies and their structures have been proposed. These compounds were used as catalysts for the reduction of pralidoxime to its amino derivative. The reduced pralidoxime was also characterized by spectral analysis and catalytic cycle has been established. The reduced product was determined spectrophotometrically by treating with ninhydrin reagent and the percent yields were found to be in the range of 75.12–82.36%.

Acinetobacter baumannii is an important nosocomial pathogen that often affects critically ill patients in intensive care units. β-Lactam antibiotics are the most commonly prescribed drugs for infectious diseases caused by A. baumannii. Our aim is to develop an accurate and rapid shotgun proteomics method for the identification of β-lactam-resistant A. baumannii pathogens. In the present study, we used automated data-dependent scanning on a nano-LC/ion trap mass spectrometer to characterize proteotypic peptides of A. baumannii. Then, we used SEQUEST software to search specific databases, the β-lactam-resistance protein database of A. baumannii (BRPDAB). We successfully found a number of associated antibiotic-resistant proteins, including AmpC, β-lactamase, and carO, in clinical resistant strains of A. baumannii and differentiated them from wild-type A. baumannii strains. We used the results of the search to identify A. baumannii pathogens and found a β-lactam-resistant clinical strain of A. baumannii using Uniprot annotations, Gene Ontology (GO), and BLAST bioinformatics tools. This proteomic study will provide a platform for the rapid diagnosis of wild-type and resistant strains of A. baumannii, which would be useful for the medical treatment of these strains.

A novel family of tetraaza macrocyclic Cu(II) complexes [CuLX2] (where L = N4 donor macrocyclic ligands) and (X = Cl−, NO3−) have been synthesized and characterized by elemental analysis, magnetic moments, IR, EPR, mass, electronic spectra and thermal studies. The magnetic moments and electronic spectral studies suggest square planar geometry for [Cu(DBACDT)]Cl2 and [Cu(DBACDT)](NO3)2 complexes and distorted octahedral geometry to the rest of the ten complexes. The biological activity of all these complexes against gram-positive and gram-negative bacteria was compared with the activity of existing commercial antibacterial compounds like Linezolid and Cefaclor. Six complexes out of twelve were found to be most potent against both gram-positive as well as gram-negative bacteria due to the presence of thio group in the coordinated ligands.

A new series of indolo[1,2-c]quinazoline derivatives were prepared in good yield through reaction of 2-(o-aminophenyl)indole with a variety of arylaldehydes. The structures of the newly synthesized compounds were confirmed by IR, (1)H NMR, (13)C NMR and mass spectral studies and elemental analysis. All the title compounds were investigated for their activity against certain strains of Gram-positive bacteria (Staphylococcus aureus, Bacillus subtilis and Streptococcus pyogenes), Gram-negative bacteria (Salmonella typhimurium, Escherichia coli and Klebsiella pneumonia) and pathogenic Fungi (Aspergillus niger, Candida albicans and Trichoderma viridae). Ampicillin and ketoconazole were used as reference compounds. The results revealed that some of synthesized compounds displayed marked activity against all the tested microorganisms.

A series of 2-o-arylidineaminophenylindoles and their cyclic derivatives (indolo[1,2-c]quinazolines) were synthesized. The reactions occurred under relatively mild conditions and afforded the desired product in good yields. Molecular structures of the synthesized compounds were confirmed by IR, (1)H-NMR,( 13)C-NMR, MS spectra, and elemental analyses. Furthermore, all the final products were screened for in-vitro antibacterial activity against three Gram-positive and three Gram-negative bacteria and also tested for their inhibitory action against three strains of fungi. Compound IIc showed potent activity against all the bacterial (except S. typhimurium) and fungal strains. Especially, compounds IIi and IIj which have isoquinolyl and pyridyl substituents displayed potent antibacterial as well as antifungal activities compared to those of the respective standard drugs Ampicillin and Ketoconazole.

With the aim of obtaining novel biologically active compounds, we have synthesized a series of mono, bis-2-o-arylideneaminophenylbenzimidazoles and a second series of corresponding mono, bis-6-arylbenzimidazo[1,2-c]quinazolines respectively. The target benzimidazo[1,2-c]quinazoline compounds were obtained by the condensation of 2-(o-aminophenyl)benzimidazole with mono and di carbonyl compounds, followed by oxidative cyclisation of the resulting mono and bis-2-o-arylideneaminophenylbenzimidazoles.All the products were characterized via IR, (1)H NMR, (13)C NMR, MS and elemental analysis. The antimicrobial activities of all quinazolines against various bacteria and fungi were evaluated. Among the compounds tested IVd, IVe exhibited good antibacterial and antifungal activities while IIIb, IIIc also showed notable antimicrobial activity with reference to standard drugs Ampicillin and Ketoconazole respectively.

A series of 2-o-arylidineaminophenylindoles and their cyclic derivatives (indolo[1,2-c]quinazolines) were synthesized. The reactions occurred under relatively mild conditions and afforded the desired product in good yields. Molecular structures of the synthesized compounds were confirmed by IR, (1)H-NMR,( 13)C-NMR, MS spectra, and elemental analyses. Furthermore, all the final products were screened for in-vitro antibacterial activity against three Gram-positive and three Gram-negative bacteria and also tested for their inhibitory action against three strains of fungi. Compound IIc showed potent activity against all the bacterial (except S. typhimurium) and fungal strains. Especially, compounds IIi and IIj which have isoquinolyl and pyridyl substituents displayed potent antibacterial as well as antifungal activities compared to those of the respective standard drugs Ampicillin and Ketoconazole.